New data from clinical trials of arbaclofen and oxytocin underscore the murkiness of null results. Plus, researchers seek clarity on the neurodevelopmental effects of oxytocin during childbirth.

Autistic toddlers who receive a personalized intervention at about 18 months of age gain more abilities than those who start the therapy nine months later.

Several studies caught researchers’ attention on social media this week, including one that compared gene expression in living versus postmortem samples of the human brain.

The findings add to the growing evidence that genes with disparate functions can play similar roles in brain development.

The chimeric mouse model could provide a more realistic way to study microglia’s roles in brain conditions such as autism.

A shift in astrocyte secretions may explain the atypical firing patterns of neurons derived from people with fragile X syndrome.

The retracted studies mar hope for the drug’s use in depression.

This week we’re highlighting social-media chatter from the INSAR 2023 meeting in Stockholm, Sweden.

Autistic children taking the drug showed improvements in some behaviors but not in their social skills.

A growing proportion of researchers has reached such “super principal investigator” status, but the distribution is not even across demographic groups.